Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02248792

Enrollment

Registered

2014-09-25

Start date

2013-11-30

Completion date

Unknown

Last updated

2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Plaque Type Psoriasis

Brief summary

Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.

Interventions

DRUGMethotrexate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA \>10% or PASI \>12) -

Exclusion criteria

Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past \-

Design outcomes

Primary

Measure	Time frame
Improvement in health related quality of life	12 weeks

Secondary

Measure	Time frame
comparison of improvement in health related quality of life between Group A and Group B	12 weeks

Countries

India

Contacts

Primary ContactC V Krishna, MD

vijay_postgradmed@yahoo.com+91-0413-2655961

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026